03:00 PM Abstract No. 218 Novel anti-glypican-3 T-cell redirecting bispecific antibody for targeted adoptive immunotherapy of hepatocellular carcinoma

We have previously reported development and synthesis of a novel T-cell redirecting bispecific antibody (bsAb) for catheter-directed targeting of glypican-3 (GPC3) on hepatocellular carcinoma (HCC) tumor cells and T-cell CD3 receptors (1). The purpose of the current study was to further investigate the efficacy of this bsAb for the activation of T-cells as well as for the induction of cytotoxicity towards HCC tumor cells in-vitro.

Source: Journal of Vascular and Interventional Radiology : JVIR - February 23, 2019 Category: Radiology Authors: P. Habibollahi, J. Hui, M. Mercadante, A. Tsourkas, G. Nadolski, S. Hunt, T. Gade Tags: Scientific Session 23: Nothing Basic About It (Basic Science Oncology) Source Type: research